Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jazz Pharmaceuticals PLC

110.04
-10.7800-8.92%
Post-market: 112.092.05+1.86%17:41 EDT
Volume:2.17M
Turnover:243.64M
Market Cap:6.68B
PE:12.72
High:117.12
Open:116.48
Low:109.76
Close:120.82
Loading ...

Company Profile

Company Name:
Jazz Pharmaceuticals PLC
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
2800
Office Location:
Waterloo Exchange,Fifth Floor,Waterloo Road,Dublin 4,Dublin,Co. Dublin,Ireland
Zip Code:
D04 E5W7
Fax:
- -
Introduction:
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Directors

Name
Position
Bruce C. Cozadd
Chairperson and Chief Executive Officer
Anne O'Riordan
Independent Director
Catherine A. Sohn
Independent Director
Heather Ann McSharry
Independent Director
Jennifer E. Cook
Independent Director
Kenneth W. O'Keefe
Independent Director
Mark D. Smith
Independent Director
Norbert G. Riedel
Independent Director
Patrick G. Enright
Independent Director
Peter Gray
Independent Director
Rick E Winningham
Lead Independent Director
Seamus C. Mulligan
Independent Director

Shareholders

Name
Position
Bruce C. Cozadd
Chairperson and Chief Executive Officer
Daniel N. Swisher, Jr.
President, Chief Operating Officer
Finbar Larkin
Senior Vice President, Technical Operations
Patricia Carr
Senior Vice President, Chief Accounting Officer
Renee Gala
Executive Vice President and Chief Financial Officer
Samantha Pearce
Senior Vice President, Europe and International
Kim Sablich
Executive Vice President and General Manager, US
Neena M. Patil
Executive Vice President and Chief Legal Officer
Robert Iannone
Executive Vice President, Global Head of Research and Development